EGFR and cancer: The pattern emerging from the first attempts to block EGFR in CRC revealed that this cancer type is addicted to EGFR‐RAS‐MAPK signaling and any perturbation to it will be likely circumvented by molecular events that are able to restore the activity of this signaling axis.